Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: since May 19, 2026 (set the dates above to see older items)
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Nov 9, 2026 | — | Bayer Healthcare | New drug (NDA) Type 1 - New Molecular Entity | NDA221291 ↗ |
| Nov 9, 2026 | OXDERYS DOXORUBICIN HYDROCHLORIDE | Avyxa Holdings | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA221093 ↗ |
| Nov 9, 2026 | MULTIBIC MULTIBIC | Fresenius Medical Care Renal Therapies Group LLC | New drug (NDA) Type 2 - New Active Ingredient | NDA219457 ↗ |
| Oct 29, 2026 | AXYCIS CISPLATIN | Avyxa Holdings, LLC | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA220748 ↗ |
| Oct 27, 2026 | LUCAMZI RANIBIZUMAB-BLRZ | Xbrane Biopharma AB | Biologic (BLA) Type 2 - New Active Ingredient | BLA761187 ↗ |
| Oct 22, 2026 | ENZEEVU AFLIBERCEPT-ABZV | Sandoz Inc | Biologic (BLA) UNKNOWN | BLA761382 ↗ |
| Oct 22, 2026 | AHZANTIVE AFLIBERCEPT-MRBB | Formycon AG | Biologic (BLA) Type 3 - New Dosage Form | BLA761378 ↗ |
| Oct 22, 2026 | PAVBLU AFLIBERCEPT-AYYH | AMGN Amgen Inc | Biologic (BLA) UNKNOWN | BLA761298 ↗ |
| Oct 20, 2026 | HIBSAGO BEPIROVIRSEN | GSK Glaxosmithkline LLC | New drug (NDA) Type 1 - New Molecular Entity | NDA221276 ↗ |
| Oct 19, 2026 | CALREZDY CALCUIM CHLORIDE | FMS Fresenius Medcl Care | New drug (NDA) Type 2 - New Active Ingredient | NDA219456 ↗ |
| Oct 19, 2026 | CIENBY SODIUM CTIRATE | FMS Fresenius Medcl Care | New drug (NDA) Type 2 - New Active Ingredient | NDA219455 ↗ |
| Oct 16, 2026 | YULZETY RIVAROXABAN | Rosemont Pharmaceuticals | New drug (NDA) Type 3 - New Dosage Form | NDA221033 ↗ |
| Oct 16, 2026 | BRYTLY APRACLONIDINE HYDROCHLORIDE | ALC Alcon Labs Inc | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA220341 ↗ |
| Oct 15, 2026 | EVOXAC CEVIMELINE HYDROCHLORIDE | Cosette | New drug (NDA) Type 3 - New Dosage Form | NDA221183 ↗ |
| Oct 9, 2026 | HOVILPRI PRITELIVIR MESYLATE | Aicuris Anti-Infect | New drug (NDA) Type 1 - New Molecular Entity | NDA221154 ↗ |
| Oct 9, 2026 | ISOVUE READI IOPAMIDOL | Bracco | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA220583 ↗ |
| Oct 8, 2026 | BREZTRI AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE | AZN Astrazeneca AB | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA220290 ↗ |
| Oct 8, 2026 | WELTRUZA OLANZAPINE | TEVA Teva | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA219007 ↗ |
| Oct 1, 2026 | TRABECTEDIN TRABECTEDIN | Ever | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA219617 ↗ |
| Sep 28, 2026 | EMCITATE TIRATRICOL | Rare Thyroid | New drug (NDA) Type 1 - New Molecular Entity | NDA220963 ↗ |
| Sep 25, 2026 | ATEBRIOZ ZILURGISERTIB FUMARATE | Mirum | New drug (NDA) Type 1 - New Molecular Entity | NDA221198 ↗ |
| Sep 25, 2026 | LAMLIQUE LAMOTRIGINE HEMIFUMARATE | Azurity | New drug (NDA) Type 2 - New Active Ingredient | NDA221109 ↗ |
| Sep 25, 2026 | JUVMO TAVAPADON | ABBV Abbvie | New drug (NDA) Type 1 - New Molecular Entity | NDA220415 ↗ |
| Sep 25, 2026 | ZUEINO DICLOFENAC SODIUM | Adventapharma | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA218379 ↗ |
| Sep 25, 2026 | DEGEVMA DENOSUMAB-ADET | TEVA Teva Pharmaceuticals, Inc. | Biologic (BLA) Type 5 - New Formulation or New Manufac… | BLA761481 ↗ |
| Sep 23, 2026 | LYRFIGTU LIRAFUGRATINIB HYDROCHLORIDE | Elevar | New drug (NDA) Type 1 - New Molecular Entity | NDA220425 ↗ |
| Sep 23, 2026 | ONSWIK INSULIN EFSITORA ALFA-GOBE | LLY Eli Lilly and Co | Biologic (BLA) Type 1 - New Molecular Entity | BLA761408 ↗ |
| Sep 22, 2026 | CARBON DIOXIDE, USP CARBON DIOXIDE, USP | Agl Welding Supply Co Inc Dba Agl Gas Technologies | New drug (NDA) UNKNOWN | NDA222000 ↗ |
| Sep 15, 2026 | GARZULYS, INSULIN DILUTING MEDIUM FOR GARZULYS INSULIN ASPART-FSAN | Emerge Bioscience Pte. Ltd. | Biologic (BLA) UNKNOWN | BLA761497 ↗ |
| Sep 14, 2026 | BEXLUTRY LUTETIUM LU-177 DOTATATE | Curium | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA218525 ↗ |
| Sep 11, 2026 | PIXCLARA FLORETYROSINE F-18 | Telix | New drug (NDA) Type 1 - New Molecular Entity | NDA218592 ↗ |
| Sep 11, 2026 | ISEMBYLD APITEGROMAB-MSTN | SRRK Scholar Rock Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761463 ↗ |
| Sep 4, 2026 | ETCAMAH CAMIZESTRANT | AZN Astrazeneca | New drug (NDA) Type 1 - New Molecular Entity | NDA220359 ↗ |
| Sep 3, 2026 | OMCAZIO CABOZANTINIB LAURYLSULFATE | Handa Oncol | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA220613 ↗ |
| Sep 3, 2026 | ZANVASTRO ZILGANERSEN SODIUM | Ionis Pharmaceuticals Inc | New drug (NDA) Type 1 - New Molecular Entity | NDA220210 ↗ |
| Aug 28, 2026 | MIMRYLO RUSFERTIDE ACETATE | TAK Takeda Pharmaceuticals Am | New drug (NDA) Type 1 - New Molecular Entity | NDA220605 ↗ |
| Aug 27, 2026 | BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM | GILD Gilead Sciences Inc | New drug (NDA) Type 4 - New Combination | NDA221443 ↗ |
| Aug 27, 2026 | BIXLENVO BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM | GILD Gilead Sciences Inc | New drug (NDA) Type 4 - New Combination | NDA221104 ↗ |
| Aug 27, 2026 | LISRAYA BREPOCITINIB TOSYLATE | Priovant Therap | New drug (NDA) Type 1 - New Molecular Entity | NDA220106 ↗ |
| Aug 26, 2026 | RASONQUE DARAXONRASIB | RVMD Revolution Medicines | New drug (NDA) Type 1 - New Molecular Entity | NDA220910 ↗ |
| Aug 26, 2026 | VOBRIG LEUPROLIDE ACETATE | Sun Pharm | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA213225 ↗ |
| Aug 19, 2026 | PASATRU GARETOSMAB-GRTS | REGN Regeneron Pharmaceuticals, Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761508 ↗ |
| Aug 14, 2026 | SODIUM BICARBONATE SODIUM BICARBONATE | BAX Baxter Hlthcare Corp | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA218524 ↗ |
| Aug 13, 2026 | ZENBEXUS IBERDOMIDE HYDROCHLORIDE | BMY Bristol Myers Squibb | New drug (NDA) Type 1 - New Molecular Entity | NDA221075 ↗ |
| Aug 13, 2026 | TAUKLARIFY FLORQUINITAU F-18 | Cerveau Lantheus | New drug (NDA) Type 1 - New Molecular Entity | NDA220496 ↗ |
| Aug 9, 2026 | NITROUS OXIDE, USP NITROUS OXIDE | Linde Gas Equip | New drug (NDA) UNKNOWN | NDA221892 ↗ |
| Aug 5, 2026 | ORZEYFUL OVEPOREXTON | TAK Takeda Pharmaceuticals USA | New drug (NDA) Type 1 - New Molecular Entity | NDA220860 ↗ |
| Jul 31, 2026 | ZIMRIXBY RITUXIMAB-CDXX | Dr Reddys Labs SA | Biologic (BLA) UNKNOWN | BLA761376 ↗ |
| Jul 29, 2026 | QLONILIK CLONIDINE HYDROCHLORIDE | CMP Dev LLC | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA221094 ↗ |
| Jul 29, 2026 | GLYCOPHOS SODIUM GLYCEROPHOSPHATE | Fresenius Kabi USA | New drug (NDA) Type 2 - New Active Ingredient | NDA220381 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 2:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates